---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-036074"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2021-07-08T23:59:59+00:00"
generated_at: "2026-06-30T06:37:04.029707+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics President/CMO resigns; CEO added as President; new director appointed

## Summary
- Dr. Amit Rakhit resigns as President and CMO effective Aug 27, 2021; will join Scientific & Clinical Advisory Board.
- Resignation not due to disagreement with company on operations, policies, or financial matters.
- CEO Jeremy M. Levin appointed President in addition to Chairman and CEO roles, effective upon Rakhit's departure.
- Robert Michael Poole appointed Class I director effective July 9, 2021, term until 2024 annual meeting.
- Poole entitled to standard non-employee director cash and equity compensation per company policy.

## SEC filing metadata
- accession: 0001564590-21-036074
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2021-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/ovid-8k_20210708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-036074
- JSON: https://secwatch.observer/filing/0001564590-21-036074.json
- Plain text: https://secwatch.observer/filing/0001564590-21-036074.txt

## Key facts
- Executive change
  Jeremy M. Levin was appointed as President at Ovid Therapeutics Inc..
  - Action: appointed
  - Role: President
  source text: the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm
- Executive change
  Robert Michael Poole was appointed as Class I director at Ovid Therapeutics Inc..
  - Action: appointed
  - Role: Class I director
  source text: the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm
- Executive change
  Dr. Amit Rakhit resigned as President and Chief Medical Officer at Ovid Therapeutics Inc..
  - Action: resigned
  - Role: President and Chief Medical Officer
  source text: Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.